GlassScriptPhysician profile
Michael H Koch
NPI 1558355719
$54,876.66
in general payments reported to CMS, 2019-2025
42 companies · $21.04 in 2025
The $21.04 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $8,100 · 2021: $2,809 · 2022: $1,640 · 2023: $914 · 2024: $21.63 · 2025: $21.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $33,144.20 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $9,765.53 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $5,387.44 | 2019-2020 | |
| Dexcom, INC. | $953.41 | 2019-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $781.14 | 2019-2023 | Freestyle Libre 3 |
| Amgen INC. | $547.72 | 2019-2024 | Evenity, Prolia |
| Medtronic, INC. | $400.09 | 2021-2025 | Auto Suture |
| Medtronic Minimed, INC. | $372.01 | 2019-2020 | |
| Lilly USA, LLC | $361.15 | 2019-2023 | Jardiance, Mounjaro, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.61 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $271.15 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $252.92 | 2019-2023 | |
| Tandem Diabetes Care, INC. | $235.00 | 2019-2022 | |
| Horizon Therapeutics Plc | $170.83 | 2019-2023 | Tepezza |
| Sanofi-Aventis U.S. LLC | $160.85 | 2019-2023 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Koch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.